In Re Pacific Fertility Center Litigation

District Court, N.D. California·Decided March 19, 2021·No. 3:18-cv-01586·Unknown

Opinion

1 2 3 4 5 6 7 UNITED STATES DISTRICT COURT 8 NORTHERN DISTRICT OF CALIFORNIA 9 10 IN RE PACIFIC FERTILITY CENTER Case No. 18-cv-01586-JSC

11 LITIGATION ORDER RE: PLAINTIFFS’ MOTION 12 TO EXCLUDE EXPERT OPINION TESTIMONY 13 Dkt. No. 632 14

16 Plaintiffs bring product liability and failure to recall claims against Chart Industries 17 following a March 2018 incident involving a Chart-manufactured cryopreservation tank which 18 was storing Plaintiffs’ eggs and embryos. In connection with summary judgment and in 19 preparation for trial, the parties each filed motions to exclude the other’s expert testimony in 20 whole or in part under the Federal Rules of Evidence and Daubert v. Merrell Dow Pharm., Inc., 21 509 U.S. 579 (1993).1 (Dkt. Nos. 629, 631, 632. 2) This Order addresses Plaintiffs’ motion to 22 exclude portions of the testimony of five of Chart’s experts. (Dkt. No. 632.) Having considered 23 the parties’ briefing regarding these motions and having had the benefit of oral argument on 24 March 4, 2021, Plaintiffs’ motion is GRANTED IN PART and DENIED IN PART as set forth 25 26 1 All parties have consented to the jurisdiction of a magistrate judge pursuant to 28 U.S.C. § 27 636(c). (Dkt. No. 553.) 1 below. 2 BACKGROUND 3 Plaintiffs in this action all obtained fertility services from Pacific Fertility Center (PFC)3, 4 and in particular, as relevant here, cryopreservation of their eggs and embryos. On March 4, 2018, 5 PFC’s laboratory director, Dr. Joseph Conaghan, discovered that Tank 4 which contained 2,500 6 embryos and 1,500 eggs—including Plaintiffs’ eggs and embryos—had lost liquid nitrogen. As a 7 result of this incident, Plaintiffs filed the underlying action against Chart alleging manufacturing 8 and design defects, as well as failure to recall.4 9 Plaintiffs contend that Tank 4 had a design and/or manufacturing defect because it was 10 designed to/should have a full-penetration weld to fuse the Tank’s liquid nitrogen fill tube to the 11 Tank’s inner vessel; instead, it had a partial penetration weld which foreseeably developed a crack 12 on the inside of the tank allowing liquid nitrogen to seep from Tank 4’s inner vessel into its 13 vacuum-insulation layer. When this occurred, the liquid nitrogen was warmed by the surrounding 14 laboratory air, transitioned from a liquid to a gas, and expanded thereby putting pressure on the 15 Tank’s inner vessel and causing it to implode. Plaintiffs also theorize that PFC had a Chart- 16 manufactured TEC 3000 electronic controller which malfunctioned two weeks prior to the incident 17 and was thus no longer being used by PFC at the time of the incident. Plaintiffs contend that a 18 functioning controller would have alerted PFC staff to the Tank’s loss of liquid nitrogen and thus 19 allowed staff to move the Tank’s contents to another tank and avoid damage. Plaintiffs maintain 20 that Chart is negligent for failing to recall or retrofit the controller because Chart was aware of 21 ongoing issues with the TEC 3000 and other Chart-manufactured controllers. 22 Chart, for its part, contends that the March 4 incident was caused entirely by PFC’s 23 negligence including PFC’s decision to unplug the TEC 3000 controller on February 15, 2018 and 24 manually monitor the liquid nitrogen level in Tank 4. Chart maintains that PFC failed to reliably 25

26 3 The Court uses PFC throughout this Order to refer to Pacific Fertility Center and all its associated entities and medical professionals, including Prelude Fertility, Inc., and Pacific MSO, 27 LLC. 1 and accurately do so and as a result the liquid nitrogen was not maintained at a level which 2 adequately controlled the temperature in Tank 4 resulting in the Tank 4 implosion. 3 Over 130 individual actions alleging these same claims against Chart have been 4 consolidated with the Plaintiffs’ claims here. The initial five Plaintiffs’ claims are scheduled for 5 jury trial May 3, 2021. 6 LEGAL STANDARD 7 Under Rule 702 of the Federal Rules of Evidence, a witness may offer expert testimony if 8 the following requirements are met:

9 (a) the expert’s scientific, technical, or other specialized knowledge will help the trier of fact to understand the 10 evidence or to determine a fact in issue;

11 (b) the testimony is based on sufficient facts or data;

12 (c) the testimony is the product of reliable principles and methods; and 13 (d) the expert has reliably applied the principles and methods 14 to the facts of the case. 15 Fed. R. Evid. 702. These criteria can be distilled to two overarching considerations: “reliability 16 and relevance.” Ellis v. Costco Wholesale Corp., 657 F.3d 970, 982 (9th Cir. 2011). The inquiry 17 does not, however, “require a court to admit or exclude evidence based on its persuasiveness.” Id. 18 Scientific evidence is reliable “if the principles and methodology used by an expert are 19 grounded in the methods of science.” Clausen v. M/V New Carissa, 339 F.3d 1049, 1056 (9th Cir. 20 2003). The court’s focus “must be solely on principles and methodology, not on the conclusions 21 that they generate.” See Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 595 (1993). The 22 court’s “task ... is to analyze not what the experts say, but what basis they have for saying it.” 23 Daubert v. Merrell Dow Pharmaceuticals, Inc., 43 F.3d 1311, 1316 (9th Cir. 1995) (hereinafter 24 Daubert II). 25 In deciding whether to permit an expert to testify, courts face the difficult task of 26 “determin[ing] whether the analysis undergirding the experts’ testimony falls within the range of 27 accepted standards governing how scientists conduct their research and reach their conclusions.” 1 (1) whether the expert’s theory or method is generally accepted in the scientific community; (2) 2 whether the expert’s methodology can be or has been tested; (3) the known or potential error rate 3 of the technique; and (4) whether the method has been subjected to peer review and publication. 4 Id. at 1316 (citing Daubert, 509 U.S. at 593-94). Consideration should also be given to whether 5 the expert’s testimony springs from research independent of the litigation. Id. at 1317. If not, the 6 expert should point to other indicia of reliability, such as peer-reviewed studies or a reputable 7 source showing that the expert “followed the scientific method, as it is practiced by (at least) a 8 recognized minority of scientists in their field.” Id. at 1317-19. “These factors are illustrative, and 9 they are not all applicable in each case.” Wendell v. GlaxoSmithKline LLC, 858 F.3d 1227, 1233 10 (9th Cir. 2017). The inquiry is “flexible,” Daubert, 509 U.S. at 594, and “Rule 702 should be 11 applied with a ‘liberal thrust’ favoring admission,” Messick, 747 F.3d at 1196 (quoting Daubert, 12 509 U.S. at 588).

Free access — add to your briefcase to read the full text and ask questions with AI

In Re Pacific Fertility Center Litigation, (N.D. Cal. 2021).

In Re Pacific Fertility Center Litigation (In Re Pacific Fertility Center Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Shawnya Jones v. Southern Pacific Railroad
962 F.2d 447 (Fifth Circuit, 1992)
Ellis v. Costco Wholesale Corp.
657 F.3d 970 (Ninth Circuit, 2011)
Stephen Wendell v. Glaxosmithkline LLC
858 F.3d 1227 (Ninth Circuit, 2017)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
43 F.3d 1311 (Ninth Circuit, 1995)
Clausen v. M/V New Carissa
339 F.3d 1049 (Ninth Circuit, 2003)